Edition:
United States

Sunshine Heart Inc (SSH.OQ)

SSH.OQ on NASDAQ Stock Exchange Capital Market

8.19USD
13 Jan 2017
Change (% chg)

$-0.66 (-7.46%)
Prev Close
$0.29
Open
$8.96
Day's High
$10.30
Day's Low
$7.81
Volume
106,513
Avg. Vol
9,394
52-wk High
$48.60
52-wk Low
$4.54

Summary

Name Age Since Current Position

John Erb

67 2016 Chairman of the Board, President, Chief Executive Officer

Claudia Drayton

47 2015 Chief Financial Officer, Secretary

Debra Kridner

63 2012 Executive Vice President - Clinical Research & Regulatory Affairs

Brian Brown

54 2014 Senior Vice President - Operations and Technology

Molly Wade

37 2014 Vice President, Worldwide Patient Recruitment and Marketing

Megan Brandt

2016 Vice President - Regulatory Affairs and Quality Assurance

Jon Salveson

50 2013 Independent Director

Gregory Waller

66 2011 Independent Director

Warren Watson

63 2013 Independent Director

Candice Knoll

2014 IR Contact Officer

Biographies

Name Description

John Erb

Mr. John L. Erb is Chairman of the Board, President, Chief Executive Officer of the Board of the Company. He has served as the Company’s Interim Chief Executive Officer and President since November 2015 and has been a director of the Company since September 2012 and Chairman of the Board since October 2012. He is co-founder of NuAx, Inc. (formerly Cardia Access, Inc.), a medical device company involved in developing new devices for the treatment of heart disease, a position he has held since February 2007. Previously, Mr. Erb served as executive chairman of the board (during 2007) and as chief executive officer (from 2001 to 2006) of CHF Solutions, Inc., a medical device company involved in the development, manufacturing and distribution of devices to treat congestive heart failure; as president and chief executive officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral vascular stents, from 1997 to 2001; and in various positions, including most recently as vice president of worldwide operations, at Schneider, a division of Pfizer, Inc., from 1991 to 1997. Mr. Erb’s prior board experience includes service as a director of SenoRx, Inc., a publicly traded company, from December 2001 to July 2010, and service as a director of CryoCath Technologies Inc., a publicly traded Canadian company, from October 2000 to December 2008. Mr. Erb currently serves as a director of NuAx, as well as Osprey Medical, Inc. (listed on the Australian Securities Exchange; serves as chairman of the compensation committee and a member of the audit committee), and Vascular Solutions, Inc. (a Nasdaq listed company; serves as chairman of the compensation and nominating and corporate governance committees). Mr. Erb received a B.A. degree in business administration, with a concentration in finance from California State University, Fullerton.

Claudia Drayton

Ms. Claudia Drayton is Chief Financial Officer, Secretary of the Company. Ms. Drayton represents the Company's third significant hire in the past 12 months from a leading cardiovascular company in the industry. Prior to joining Sunshine Heart, Ms. Drayton spent the past fifteen years at Medtronic, Inc, a $17B global leader in the medical device industry. During her tenure, she held multiple senior managerial finance positions culminating with an assignment in Europe serving as Chief Financial Officer of the Peripheral Vascular Business (2010-2012) and most recently, as Chief Financial Officer and Senior Finance Director of the Integrated Health Solutions Business. In these capacities her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, and implementation of financial best practices. Before Medtronic, Ms. Drayton was an Audit and Business Advisory Manager at Arthur Andersen for seven years. She holds an MBA from the University of Minnesota's Carlson School of Management, a BS from the University of Mary Hardin-Baylor and is a Certified Public Accountant (inactive).

Debra Kridner

Ms. Debra J. Kridner is Executive Vice President - Clinical Research & Regulatory Affairs of Sunshine Heart, Inc. From October 2012 to August 2013, Ms. Kridner also held the position of Executive Vice President of Clinical Research. Previously, Ms. Kridner was our Vice President of Clinical Research and Regulatory Affairs, from November 2009 to March 2010, on a consultant basis, and from March 2010 to October 2012, as an employee of Sunshine Heart. From 2008 to 2009, Ms. Kridner worked as a consultant for her company, Kridner Consulting LLC, which performed consulting services for medical device companies. From 2004 to 2008, Ms. Kridner served as the Vice President of Clinical Research, Quality and Regulatory Affairs for St. Jude Medical’s Cardiac Surgery and Interventional Cardiology for the Cardiovascular Division.

Brian Brown

Mr. Brian Brown is Senior Vice President - Operations and Technology of the Company. In this capacity, Mr. Brown will manage the Company's R & D program for its flagship C-Pulse® Heart Assist System, a medical device addressing Class III and ambulatory Class IV heart failure. Additionally, Mr. Brown will be responsible for operations inclusive of internal and contracted manufacturing. Mr. Brown comes to Sunshine Heart after serving as R & D, Vice President Cardiovascular at Boston Scientific for the past 10 years. Prior to joining Boston Scientific in 1994, he held multiple engineering and managerial roles at SciMED Life Systems Inc., a developer and marketer of medical devices used principally to treat cardiovascular disease which was acquired by Boston Scientific. Mr. Brown has spent 24 years in the medical device industry including senior managerial roles at Boston Scientific where he most recently held the position of R & D, Vice President, Cardiovascular from 2004-2014, and SciMED Life Systems which was acquired by Boston Scientific in 1994. Boston Scientific is an international, publicly traded company headquartered in Boston, MA focused on the design, manufacture, and sale of minimally invasive medical devices in the areas of disposable devices (single use), permanent implants, and combination drug devices. The Interventional Cardiology business unit represents a $2B division of the company's greater than $7B of annual revenue. As R & D, VP of Cardiovascular, Brian directed the multisite worldwide research and development activities for the accelerated multi-billion dollar launches of implantable stents, drug delivery technologies, disposable catheters and adjunctive devices. Mandates typically evolved from early exploratory work, to technology development projects, to product commercialization, followed by line extensions or sustaining activities. Brian holds a Bachelor of Science, Mechanical Engineering with an emphasis on electro -mechanical automation from North Dakota State University.

Molly Wade

Ms. Molly Wade is our Vice President of Worldwide Patient Recruitment and Marketing, a position she has held since August 2014. Ms. Wade joined the Company in October 2013 as Senior Director of U.S. Patient Recruitment. Prior to joining the Company, Ms. Wade spent six years at CVRx, a small privately held company, conducting clinical research in both hypertension and heart failure. She previously worked for Medtronic, C.R. Bard, and Eli Lilly in various sales capacities. Ms. Wade holds a B.S. in Health Science/Marketing from the University of Minnesota, Twin Cities (School of Public Health/Carlson School of Management).

Megan Brandt

Ms. Megan Brandt is Vice President - Regulatory Affairs and Quality Assurance of the Company. Prior to joining Sunshine Heart, Ms. Brandt was Vice President of Quality and Regulatory Affairs at Cardiovascular Systems, Inc. (CSI), a company focused on developing and commercializing innovative solutions for treating peripheral and coronary vascular disease. At CSI, she successfully facilitated domestic and international clinical study submissions and secured multiple regulatory approvals including CE mark, 510(k) clearances, and original PMA approval for their peripheral and coronary orbital atherectomy systems. She currently serves as Co-Chair for Medical Alley's Regulatory Advisory Board and is actively involved in FDA working groups including Harmonization by Doing and MDEpiNet's RAPID programs. In 2014, she was nominated by Minnesota Business Magazine as an Emerging Healthcare Leader. Ms. Brandt earned her B.S. in Biochemistry and Microbiology from Minnesota State University-Mankato.

Jon Salveson

Mr. Jon W. Salveson is Independent Director of Sunshine Heart Inc since March 13, 2013. Mr. Salveson is the Vice Chairman, Investment Banking and Chairman of the Healthcare Investment Banking Group at Piper Jaffray Companies. He also serves on the board of CryoLife, a medical device company focused on cardiac and vascular surgery. Mr. Salveson joined Piper Jaffray in 1993 as an associate, was elected Managing Director in 1999, and was named the Group Head of Piper Jaffray’s International Healthcare Investment Banking Group in 2001. Mr. Salveson was appointed Global Head of Investment Banking and a member of the Executive Committee of Piper Jaffray in 2004, and has served in his present position as Vice Chairman, Investment Banking since July 2010. Mr. Salveson started his career as a market manager at Bio-Metrics Systems (now part of Surmodics, Inc.), an innovator in medical device surface modification, where he gained experience working in cardiology and interventional medicine.

Gregory Waller

Mr. Gregory D. Waller is Independent Director of Sunshine Heart Inc., since August 3, 2011. Mr. Waller also serves on the board of Endologix Corporation, a publicly traded company, as Audit Committee Chairman, and is currently the Chief Financial Officer of Ulthera Corporation, a privately held company that sells an ultrasound device used for non-invasive brow lifts. From March 2006 until April 2011, Mr. Waller was Chief Financial Officer of Universal Building Products, Inc., a manufacturer of concrete construction accessories. Mr. Waller served as Vice President of Finance, Chief Financial Officer, and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement in May 2005, and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller joined Ormco Corporation in December 1980 as Vice President and Controller and served as Vice President of Kerr European Operations from July 1989 to August 1993. Mr. Waller has an M.B.A. with a concentration in Accounting from California State University, Fullerton. He also served on the board of directors and audit committee of Cardiogenesis Corporation, a publicly traded company, until its acquisition by Cryolife, Inc. in 2011. Mr. Waller also served on the boards of directors of Alsius Corporation, a publicly traded company, from June 2007 to September 2009, until its acquisition by Zoll Medical Corporation; Biolase Technology, Inc., a publicly traded company, from October 2009 to August 2010; Clarient, Inc., a publicly traded company which was acquired by General Electric Company on December 22, 2010; and SenoRx, a publicly traded company which was acquired by C.R. Bard, Inc. on July 6, 2010.

Warren Watson

Mr. Warren S. Watson serves as a Independent Director of Sunshine Heart, Inc., since January 29, 2013. Mr. Watson is an executive with over 35 years of experience in the field of medical devices. Since 1982, Mr. Watson has served on the board of directors of Citizens Independent Bank of St. Louis Park, Minnesota, a community bank with four branches and $300 million in assets. From 2010 to 2012, he served as the Executive Chairman of Cameron Health Inc., a medical technology company focused on subcutaneous implantable cardioverter and defibrillator devices. From 2004 to 2009, Mr. Watson served as a director for CardioMems, Inc., a start-up company focused on pulmonary artery pressure monitoring for patients with heart failure. From 2002 to 2009, Mr. Watson served as Vice President of Cardiac Rhythm Management Research and Development, an organization leading over 1,800 professionals worldwide; he also served as Chair of the Medtronic Corporate Research and Development Council during his tenure with the organization. From 2002 to 2007, Mr. Watson served as the Vice President and General Manager of the San Jose-based CardioRhythm cardiac ablation business.

Candice Knoll

Basic Compensation